Evidence map›Paper›PMID 27293853›Full record

ArticleJournal of thoracic disease2016

Complete response of myeloid sarcoma with cardiac involvement to radiotherapy.

Wen-Chi Yang, Ming Yao, Yu-Hsuan Chen, Sung-Hsin Kuo

Open access · hybridAbstract read
In one paragraph

Article in Journal of thoracic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cardiac Myeloid Sarcoma: Review of Literature.Journal of clinical and diagnostic research : JCDR · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wen-Chi Yang1 Division of Radiation Oncology, Department of Oncology, 2 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan ; 3 Cancer Research Center, 4 Graduate Institute of Oncology, National Taiwan University College of Medicine and National Taiwan University Cancer Center, Taipei, Taiwan.
Ming Yao1 Division of Radiation Oncology, Department of Oncology, 2 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan ; 3 Cancer Research Center, 4 Graduate Institute of Oncology, National Taiwan University College of Medicine and National Taiwan University Cancer Center, Taipei, Taiwan.
Yu-Hsuan Chen1 Division of Radiation Oncology, Department of Oncology, 2 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan ; 3 Cancer Research Center, 4 Graduate Institute of Oncology, National Taiwan University College of Medicine and National Taiwan University Cancer Center, Taipei, Taiwan.
Sung-Hsin Kuo1 Division of Radiation Oncology, Department of Oncology, 2 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan ; 3 Cancer Research Center, 4 Graduate Institute of Oncology, National Taiwan University College of Medicine and National Taiwan University Cancer Center, Taipei, Taiwan.
National Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a rare case of intracardiac myeloid sarcoma (MS) of acute myeloid leukemia (AML) and who responds completely well to low-dose radiotherapy. This 19-year-old young man initially presented with AML and received standard chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, he developed intracardiac isolated MS relapse with the presentation of exertional dyspnea and superior vena cava (SVC) syndrome 3 years later. He then received radiotherapy with 24 Gy at a 12 daily fractions using forward "field in field" intensity modulated radiotherapy technique. He dramatically had improved clinical symptoms, and complete remission was achieved one month after completing radiotherapy. Our result is in line with anecdotal case reports showed that radiotherapy with 15 Gy in 10 fractions or with 24 Gy in 12 fractions resulted in good response and less toxicity of 2 cases of MS with cardiac involvement. These results indicate that a modest radiotherapy dose, 24 Gy, achieves good local control of MS with cardiac involvement.

Indexed as

Heartmyeloid sarcomaradiotherapy

Identifiers

PMID27293853
PMCPMC4885973
OpenAlexW2400514146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.